Home  /  Resource Library  /  A Phase II Study of Brentuximab Vedotin in the Treatment of Elderly Hodgkin Lymphoma Patients at First Relapse or with Primary Refractory Disease

A Phase II Study of Brentuximab Vedotin in the Treatment of Elderly Hodgkin Lymphoma Patients at First Relapse or with Primary Refractory Disease

Results of a phase II study investigating brentuximab vedotin for treatment of relapsed Hodgkin in elderly patients.